Silence Therapeutics GmbH
🇩🇪Germany
Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
Phase 1
Completed
- Conditions
- Carcinoma, Pancreatic Ductal
- Interventions
- Drug: Atu027 & gemcitabine in lead in safety periodDrug: Atu027 & gemcitabine in treatment arm 1Drug: Atu027 & gemcitabine in treatment arm 2
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Silence Therapeutics GmbH
- Target Recruit Count
- 29
- Registration Number
- NCT01808638
- Locations
- 🇩🇪
Klinikum Stuttgart Klinik Hämatologie, Onkologie und Palliativmedizin, Stuttgart, Germany
🇩🇪Medizinische Klinik III - Hämatologie/Onkologie Marienhospital Herne, Herne, Germany
🇩🇪Klinikum Dortmund gGmbH Medizinische Klinik Mitte, Dortmund, Germany
Study With Atu027 in Patients With Advanced Solid Cancer
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Silence Therapeutics GmbH
- Target Recruit Count
- 34
- Registration Number
- NCT00938574
- Locations
- 🇩🇪
Dept. of Hematology & Med. Oncology, Univ. of Bochum, Marienhospital Herne, Herne, Germany
© Copyright 2025. All Rights Reserved by MedPath